Immunocore wins Financing Deal of the Year at the 12th Annual SCRIP Awards 2016
(Oxford, UK, 1st December 2016) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, was awarded Financing Deal of the Year at last night’s SCRIP awards at the Grosvenor House Hotel, Park Lane, London.
2016 has been a stellar year for Immunocore, fuelled by the Company’s record-breaking $320 million series A financing round to advance its lead programme, IMCgp100. The Company used the financing to advance its ImmTAC programmes through clinical development and strengthen its strategic partnerships, including the launch of a Phase I combination therapy trial with MedImmune. Immunocore also expanded its infectious disease pipeline, with data published the journal Molecular Therapy, demonstrating the potential of novel antiviral drugs to kill HIV-infected cells.
Eliot Forster, Chief Executive Officer of Immunocore, commented: “This award is a tribute to the hard work and commitment of the whole team behind the $320 million Series A financing round and all of Immunocore’s staff, Board and investors. This private capital has enabled Immunocore to continue to work towards bringing our technology to patients, having announced positive clinical data with our lead programme, IMCgp100, in metastatic, uveal and cutaneous melanoma, advanced our strategic partnerships and progressed additional ImmTAC programmes towards the clinic.”
The SCRIP Awards, now in its 12th year, is among the most prestigious in the calendar for the life sciences industry. The Financing Deal of the Year Award seeks to reward successful and creative fundraising by pharma and biotech companies.
Please click on the link below to download the full Press Release: